Abstract
The environment of business development on regenerative medicine in Japan was drastically changed by the Pharmaceuticals and Medical Devices, etc. Act and the Regenerative Medicine Act that were enforced on November 25th, 2014. In parallel, the situation surrounding health and medical innovation in Japan is also changing. In this article we interviewed Professor Ryuichi Morishita, a member of the Council for Regulatory Reform, to discuss the trend of medical regulatory reform in Japan.
